Presented by Laura Neville, ND | August 5, 2026 at 12 PM Pacific

Learning Objectives:

• Explain the role of mitochondria in cellular energy production and endocrine function.
• Describe how hormones regulate mitochondrial biogenesis, metabolism, and oxidative stress.
• Recognize clinical conditions associated with hormone-driven mitochondrial dysfunction.
• Identify laboratory and functional assessments that may aid in evaluating mitochondrial health.
• Apply evidence-informed strategies to support mitochondrial function and optimize metabolic and hormonal health.

Presented by Heather Hydzik, ND | September 2, 2026 at 12 PM Pacific

Cardiovascular disease is the leading cause of death worldwide yet is often preventable, emphasizing a need for better early screening measures. In 2026, the American College of Cardiology (ACC) and American Heart Association (AHA) issued new guidelines for calculating cardiovascular risk, as well as incorporating more precise markers like high-sensitivity C-reactive protein (hs-CRP), lipoprotein (a) (Lp(a)), apolipoprotein B (apoB), because monitoring LDL as the sole representative of risk is not sufficient.

Routine laboratory testing like fasting glucose and the lipid panel can fail to identify individuals at high risk of atherosclerosis and insulin resistance, and this is why more advanced lipid testing and metabolic and inflammatory lab markers are needed to more precisely distinguish high risk patients for whom lifestyle changes and medications could increase lifespan and enhance the proportion of time spent in good health.

Through patient cases, we will discover how to more precisely assess and decrease cardiometabolic risk by identifying particle burden, inflammation, insulin resistance, and genetics through measurement of hs-CRP, adipokines, apoB, Lp(a) and more. Learn to interpret precision cardiometabolic biomarkers and help patients gain control of their health today.

Learning Objectives:

• Recognize the limitations of standard lipid panels and routine labs for assessment of ASCVD and metabolic risk.
• Incorporate advanced biomarkers, including those recommended in the updated 2026 ACC/AHA guidelines to enhance early detection of cardiometabolic risk and guide personalized treatment strategies.
• Appreciate the contribution of nutrition and lifestyle to the balance between atherogenic and anti-atherogenic lipoproteins, to enable counsel on effective therapies including behavior change, supplementation, and medication